GLP-1 medications have been around since early 2000s but only recently started getting more media coverage, thanks to celebrities and influencers. In this episode of Real-Time, Real Talk host Cher Pastore speaks to acclaimed Timothy Gilbert, MD, a clinical endocrinologist with over 15 years of experience in diabetes management. He has a practice in Louisiana where he and his team, including physicians, nurses, dieticians, and diabetes care and education specialists see many patients every day. Dr Gilbert will demystify this extremely popular weight loss drug, explain the clinical indications for use, when it is beneficial for the patient, and in what scenario GLP-1 may or may not be the best choice. Using examples from his practice, he will answer the question we all been waiting for: how does CGM and GLP-1 medication work together, and what key role CGM plays in optimizing therapy. Cher says this is her favorite episode to date, so definitely not one to be missed! Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide (https://bit.ly/3MSkRUv). For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Timothy R Gilbert, MD is a paid spokesperson for Dexcom. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. Dexcom Provider website: https://provider.dexcom.com/ Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

In this episode of Dexcom’s Real Time Real Talk, we’re speaking to Tandem’s Medical Director, Jordan Pinsker. Jordan is a pediatric endocrinologist by training, but has been involved in clinical trials and the development of automated insulin delivery products for many years. Our second guest is Kristy Castillo, the clinical solutions manager at Tandem who is also a nurse, diabetes educator and  lives with type one diabetes herself.   We’ll discuss Tandem products including the sleek new number 1 one rated AID system, the t:slim X2 insulin pump, we’ll talk about how it integrates with the Dexcom G6 and G7 and Kristy also shares her first-hand experience of using it.   Finally we’ll discuss the advantages of connecting your AID system to your smartphone where possible, not just for those with diabetes but also for health care professionals. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Dr Jordan Pinsker and Kristy Castillo are employees of Tandem Diabetes Care. About Tandem Diabetes Care: https://www.tandemdiabetes.com/en-gb/home Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. Dexcom Provider website: https://provider.dexcom.com/ Tandem Control IQ Clinical Evidence: https://www.tandemdiabetes.com/en-gb/home References: 1. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021 Sep;23(9):601-608. doi: 10.1089/dia.2021.0097. Epub 2021 Apr 21. PMID: 33784196; PMCID: PMC8501470. 2. Roy W. Beck, Lauren G. Kanapka, Marc D. Breton, Sue A. Brown, R. Paul Wadwa, Bruce A. Buckingham, Craig Kollman, and Boris Kovatchev.A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.Diabetes Technology & Therapeutics.May 2023.329-342.http://doi.org/10.1089/dia.2022.0558 3. S.A. Brown, B.P. Kovatchev, D. Raghinaru, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes N Engl J Med 2019;381:1707-17. DOI: 10.1056/NEJMoa1907863 4. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP; iDCL Trial Research Group. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. N Engl J Med. 2020 Aug 27;383(9):836-845. doi: 10.1056/NEJMoa2004736. PMID: 32846062; PMCID: PMC7920146. 5. Marc D. Breton and Boris P. Kovatchev One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology, Diabetes Technology & Therapeutics 2021 23:9, 601-608 6. Boris P. Kovatchev, Harsimran Singh, Lars Mueller, Linda A. Gonder-Frederick; Biobehavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis. Diabetes Care 1 November 2022; 45 (11): 2636–2643. https://doi.org/10.2337/dc22-1217

This is our third and final episode which was recorded at ADA – The American Diabetes Association conference held in San Diego earlier this year. In this episode, host Cher Pastore speaks to Dr Maggie Crawford, senior manager of translational and behavioral data science at Dexcom, to discuss findings from a few studies Dr Crawford was presenting at ADA. The first study, titled "Exploring the Impact of CGM on Perceived Control and Non-Intensive Insulin Treated Type Two Diabetes", explored how CGM use influenced individuals' perceptions of control over their diabetes. Participants monitored their glucose levels with Dexcom's CGM system over a three month period with no behavioural support. The second study investigated the impact of Dexcom's G6 real-time CGM on glucose metrics, self-reported body weight, and psychosocial health among customers living with type two diabetes and taking basal insulin. Maggie has a PhD public health, focusing on health behavior, and also earned a masters in public health in epidemiology. Maggie's personal and career goal is to help people understand their physiology and behaviors to help them feel in control of managing their health. She spends her free time surfing, backcountry skiing, climbing, running, and mountain biking-- and playing with her two vivacious babies. Her greatest accomplishment has been birthing two amazing humans 18 months apart while managing type 1 diabetes. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. Dr Margaret Crawford is an employee of Dexcom. BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. Dexcom Provider website References: 1. MARGARET A. CRAWFORD, CHRISTIAN HICKS, PAUL GENGE, KENNETH GREENAWALD, MICHELLE TRESSLER, DANIEL R. CHERÑAVVSKY, HARSIMRAN SINGH; 677-P: Exploring the Impact of CGM on Perceived Control of Non-Intensive Insulin Treated Type 2 Diabetes—“I liked keeping my line with as few spikes as possible”. Diabetes 20 June 2023; 72 (Supplement_1): 677–P. https://doi.org/10.2337/db23-677-P 2. MARGARET A. CRAWFORD, CHRISTIAN HICKS, TERESA ZHOU, AFSHAN KLEINHANZL, HARSIMRAN SINGH; 63-LB: Real-Time Continuous Glucose Monitoring (rtCGM) Is Associated with Improved Clinical and Psychosocial Health in People with Type 2 Diabetes on Basal Insulin (T2D-BI). Diabetes 20 June 2023; 72 (Supplement_1): 63–LB. https://doi.org/10.2337/db23-63-LB

In the latest episode of Real Time Real Talk, we engage in an enlightening conversation on the progressive strides in diabetes management with our special guest, Dr. Nicholas Argento. With personal experience spanning over five decades of living with type one diabetes and leveraging his professional expertise in diabetes technology, Dr. Argento details the indispensable role that CGM plays in his life from diagnosis in 1968, the evolution of glucose monitoring, ie. From insulin to now integrating CGM with an automated insulin delivery devices and what the future could hold. In this insightful discussion, Dr. Argento also offers his first-hand experience with the Dexcom G6 device, drawing parallels between CGM and a personal GPS for glucose. He elaborates on the downside of the traditional finger sticks method of monitoring blood glucose levels and champions the CGM as a significant milestone in diabetes management. He also shares actionable strategies for dietary adjustments and lifestyle modification, emphasizing the link between diet, light exercises, and effective blood glucose level management. This is a fantastic episode with great takeaways, not just for those living with diabetes but also health care professionals. This episode was recoded at ADA - The American Diabetes Association in July 2023. Real-time real talk is intended for healthcare professionals in the US. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Dr. Nicholas Argento MD, PhD is a paid spokesperson for Dexcom. About Hello Dexcom Dexcom Provider website Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References: 1. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021 Sep;23(9):601-608. doi: 10.1089/dia.2021.0097. Epub 2021 Apr 21. PMID: 33784196; PMCID: PMC8501470. 2. Tadej Battelino, et al; Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 1 August 2019; 42 (8): 1593–1603. https://doi.org/10.2337/dci19-0028

Join us for an insightful journey into the world of diabetes management technology on this very special episode of Real-Time, Real Talk. Recorded live from the American Diabetes Association’s 83rd Scientific Sessions in San Diego, host Nancy Hanna is joined by Dexcom’s Cher Pastore in our very first simulcast. To explore how Dexcom and Omnipod are influencing the dynamics of diabetes technology and reshaping patient outcomes for the better, they’re joined by Dr. Viral Shah - an endocrinologist whose research into these innovative therapies has touched and improved countless lives. Across the episode, you'll discover how technological advancements are changing the game and reducing daily management burdens for people with diabetes. Hear invaluable insights from Dr. Shah on the importance of early adoption of tools and how they can prove pivotal in managing diabetes and improving glycemic control. Dr Shah examines the different barriers to technology adoption, and how fostering a pro-active conversation can help overcome them. All this, plus a sneak peek into the future of diabetes tech. Real-time real talk is intended for healthcare professionals in the US. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G6 User Guide (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G6-CGM-Users-Guide-new.pdf). For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G6 app or receiver before making treatment decisions. Dr. Viral Shah MD, is a paid spokesperson for Dexcom. About Hello Dexcom (https://provider.dexcom.com/prescribe-sample#block-contactus) Dexcom Provider website (https://provider.dexcom.com/) Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References: 1. Sue A. Brown, et al, Omnipod 5 Research Group; Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care 1 July 2021; 44 (7): 1630–1640. https://doi.org/10.2337/dc21-0172 2. Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022 Mar 1;45(3):750-753. doi: 10.2337/dc21-2004. 3. Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. Diabetes Technol Ther. 2019 Jan;21(1):6-10. doi: 10.1089/dia.2018.0257. 4. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=52464&ver=49&contractorName=all&sortBy=updated&bc=13 5. Davis GM, Peters AL, Bode BW, Carlson AL, Dumais B, Vienneau TE, Huyett LM, Ly TT. Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy. Diabetes Care. 2023 Apr 1;46(4):742-750. doi: 10.2337/dc22-1915. 6. Davis GM, et al. Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multi-Center, Single-arm, Feasibility Trial. Diabetes Technol Ther. 2023 Aug 14. doi: 10.1089/dia.2023.0304.

In this month’s episode of Dexcom’s ‘Real Time Real Talk', host Cher Pastore talks to Beta Bionic’s Chief Medical Officer, Dr. Steven Russell about the iLet Bionic Pancreas - the revolutionary automated insulin delivery system from ADA - The American Diabetes Association held in San Diego. The iLet has been years in the making with Dr Ed Damiano, Beta Bionic’s founder starting this journey when his son was diagnosed with T1 diabetes aged just 11 months, to back in May when Beta Bionics have announced FDA Clearance and Commercialization of the iLet. Founded in 2015 explicitly to be a force for good for the diabetes community, the iLet ticks that box as it reduces the need to make decisions about your diabetes management – as it makes the decisions for you. No more carb counting, carb ratios, correction factors or pre-set Basal rates, How does it do that? By using a few algorithms: Basal, corrections and meal dose, and all you need to do to get started is to put your body weight in! Topics discussed in this episode include the journey of how the iLet came to be and how it differs from other automated insulin delivery systems in that it solves two notable challenges that have long burdened both type 1 diabetics and healthcare providers — carbohydrate counting and pre-bolusing. Dr Russell also discusses some of the findings from the extensive pivotal trials that took place, how the iLet is working with the Dexcom G6, some findings from the targeted initial launch and the roadmap Beta Bionics are planning for the future of the iLet. Whether you’re using the iLet, want to use it or are a Health Care Provider, this episode is not one to miss out. Real-time real talk is intended for healthcare professionals in the US. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide (https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G7-CGM-Users-Guide.pdf). For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. In this month’s episode of Dexcom’s ‘Real Time Real Talk', host Cher Pastore talks to Beta Bionic’s Chief Medical Officer, Dr. Steven Russell about the iLet Bionic Pancreas - the revolutionary automated insulin delivery system from ADA - The American Diabetes Association held in San Diego. The iLet has been years in the making with Dr. Ed Damiano, Beta Bionic’s founder starting this journey when his son was diagnosed with T1 diabetes aged just 11 months, to back in May when Beta Bionics have announced FDA Clearance and Commercialization of the iLet. Founded in 2015 explicitly to be a force for good for the diabetes community, the iLet ticks that box as it reduces the need to make decisions about your diabetes management – as it makes the decisions for you. No more carb counting, carb ratios, correction factors or pre-set Basal rates, How does it do that? By using a few algorithms: Basal, corrections and meal dose, and all you need to do to get started is to put your body weight in! Topics discussed in this episode include the journey of how the iLet came to be and how it differs from other automated insulin delivery systems in that it solves two notable challenges that have long burdened both type 1 diabetics and healthcare providers — carbohydrate counting and pre-bolusing. Dr. Russell also discusses some of the findings from the extensive pivotal trials that took place, how the iLet is working with the Dexcom G6, some findings from the targeted initial launch and the roadmap Beta Bionics are planning for the future of the iLet. Whether you’re using the iLet, want to use it or are a Health Care Provider, this episode is not one to miss out. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Dr. Steven Russell MD, PhD is a Chief Medical Officer of Beta Bionics. About Hello Dexcom: https://provider.dexcom.com/prescribe-sample#block-contactus Dexcom Provider website: https://provider.dexcom.com/ About Beta Bionics: https://www.betabionics.com/ Warning: Do not use the Dexcom G7 CGM System or the Dexcom G6 System if you are on dialysis. The performance of these CGM systems has not been evaluated in this population and sensor readings may be inaccurate. BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References: 1. Lynch J, Kanapka LG, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Calhoun P, Beck RW. The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct;24(10):726-736. doi: 10.1089/dia.2022.0341. PMID: 36173238; PMCID: PMC9529297. 2. Beck RW, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Li Z, Calhoun P. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct;24(10):681-696. doi: 10.1089/dia.2022.0167. PMID: 36173235; PMCID: PMC9529301. 3. Kruger D, Kass A, Lonier J, Pettus J, Raskin P, Salam M, Trikudanathan S, Zhou K, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro C, Li Z, Marak MC, Calhoun P, Beck RW. A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 Oct;24(10):697-711. doi: 10.1089/dia.2022.0200. PMID: 36173236; PMCID: PMC9634987.

In this podcast episode, host Cher Pastore speaks with Dr Sushma Reddy, a clinical endocrinologist at Carbon Health, a tech-enabled healthcare company on a mission to make great healthcare accessible by putting people first. Dr Reddy has used CGM for over 20 years and has developed innovative approaches to manage diabetes that incorporate CGM including a boot camp approach to uncontrolled type 2 diabetes, a CGM clinic and a therapeutic CGM training program. As an endocrinologist at Carbon Health, she sees patients completely virtually using a team based approach incorporating CGM. We discuss how the use of CGM and digital platforms can help improve outcomes for patients, she shares stories of patients using CGM and shares insights for other health care providers. Real-time real talk is intended for healthcare professionals in the US. DISCLAIMER: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the: Dexcom G7 User Guide: https://bit.ly/3MSkRUv For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. DEXCOM CLARITY SAFETY INFORMATION: The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. About Hello Dexcom: https://www.dexcom.com/en-us/get-started-cgm/11 Dexcom Provider website: https://provider.dexcom.com/

In this podcast episode, host Cher Pastore speaks with Cup of OJ Founder, Ariana Frayer, who was diagnosed with type 1 diabetes aged 10. Ariana shares her journey, what it was like growing up with diabetes, and how it impacted things like school and dating. We also hear about her unique experience with CGM, what she likes about the G7, the differences from the G6 as well as her favourite features. Lastly, we learn about a community she founded on Instagram and Cup of OJ to pursue her goal of sharing knowledge and inspiring growth, keeping herself accountable for her diabetes whilst uniting others who also share this experience. Real-time real talk is intended for healthcare professionals in the US. DISCLAIMER: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the: Dexcom G7 User Guide: https://bit.ly/3MSkRUv For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Ariana Frayer is a paid spokesperson and a Dexcom Warrior. BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. DEXCOM CLARITY SAFETY INFORMATION: The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. About Hello Dexcom: https://www.dexcom.com/en-us/get-started-cgm/11 Dexcom Provider website: https://provider.dexcom.com/

Real-time real talk is intended for healthcare professionals in the US. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individualresults may vary – nothing you hear on this podcast should be considered medical advice. All claims are supportedby clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 UserGuide. For product-related questions, please refer to the instructions for use. For complete safety information, goto dexcom.com/safety-information.Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucosemonitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has nolimitations for use in pregnancy.About New Expanded Medicare GuidelinesAbout Hello DexcomDexcom Provider websiteAbout Medicaid coverageDexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.Data from collaborator devices and products must be verified by those collaborator devices and products. Usersshould confirm data and connections with their collaborator devices and products.A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends.CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatmentdecisions.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and itscomponents according to the instructions for use provided with your device and available athttps://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings,precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low bloodglucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result ininjury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to makediabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medicalemergency.Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals toassist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historicalCGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGMdevices with data interface capabilities. Caution: The software does not provide any medical advice and should notbe used for that purpose. Home users must consult a healthcare professional before making any medicalinterpretation and therapy adjustments from the information in the software. Caution: Healthcare professionalsshould use information in the software in conjunction with other clinical information available to them. Caution:Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S.,and may be registered in other countries.References1. Dexcom G7 User Guide2. Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control inPatients With Type 2 Diabetes Treated With Basal Insulin: A Randomized ClinicalTrial. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.74443. Aleppo G, et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2Diabetes Treated With Basal Insulin. Diabetes Care. 2021 Dec;44(12):2729-2737. doi: 10.2337/dc21-1304

Real-time real talk is intended for healthcare professionals in the US. Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.   Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. Amy Valent, MD is a paid spokesperson for Dexcom and is a guest on this episode of the podcast. About Hello Dexcom   Dexcom Provider website   Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products.   A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References Dexcom G7 User Guide Satish K. Garg, MD, et al. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes.Diabetes Technology & Therapeutics.Jun 2022.373 380.http://doi.org/10.1089/dia.2022.0011. Denice S Feig, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.